ViferaXS raises €12M Series A to push leukemia therapy into Phase II
What's the deal? ViferaXSDealroom has a profile for this one. Try Dealroom →, a Tübingen-based clinical-stage biotech, has closed a €12 million Series A, including grant funding. The round was led by SPRIND, the German Federal Agency for Breakthrough Innovation, and Huma, with participation from private investors.
What's the endgame? The company develops peptide-based cancer immunotherapy for blood cancers and solid tumors. The proceeds will fund a Phase II trial of its lead programme, CLLTAXS01, in chronic lymphocytic leukemia.
Why now? ViferaXS points to early clinical results as the trigger. "We are encouraged by the early clinical data of CLLTAXS01, and this financing lets us move that signal into a randomized Phase II study in CLL," said chief executive officer Sezai Taskin.
The money also supports ongoing Phase I programmes in acute myeloid leukemia and fibrolamellar carcinoma, with read-outs expected soon. Beyond that, ViferaXS plans to grow its team and advance preclinical work in further indications.
What could go wrong? Clinical-stage biotech carries binary risk. A Phase II miss in CLL, or weak Phase I data from the AML and FLC programmes, would undercut the case for the peptide approach.
The signal: At €12 million, this is a modest raise by biotech standards — sitting in the lower tier of comparable rounds. But SPRIND's lead role signals German state backing for high-risk science. "ViferaXS' peptide-based cancer immunotherapy approach, and its move into Phase II in CLL, is the kind of clinically grounded, high-ambition work we seek to accelerate," said Patrick Rose, innovation manager at SPRIND.
Read more: wallstreet-online.de
Image credit: ViferaXS
